Direkt zum Inhalt
Merck
  • Transcriptome profiling identifies p53 as a key player during calreticulin deficiency: Implications in lipid accumulation.

Transcriptome profiling identifies p53 as a key player during calreticulin deficiency: Implications in lipid accumulation.

Cell cycle (Georgetown, Tex.) (2015-05-07)
Saurabh Vig, Puneet Talwar, Kirandeep Kaur, Rohit Srivastava, Arvind K Srivastava, Malabika Datta
ZUSAMMENFASSUNG

Calreticulin (CRT) is an endoplasmic reticulum (ER) resident calcium binding protein that is involved in several cellular activities. Transcriptome analyses in CRT knockdown HepG2 cells revealed 253 altered unique genes and subsequent in silico protein-protein interaction network and MCODE clustering identified 34 significant clusters, of which p53 occupied the central hub node in the highest node-rich cluster. Toward validation, we show that CRT knockdown leads to inhibition of p53 protein levels. Both, CRT and p53 siRNA promote hepatic lipid accumulation and this was accompanied by elevated SREBP-1c and FAS levels. p53 was identified to bind at -219 bp on the SREBP-1c promoter and in the presence of CRT siRNA, there was decreased occupancy of p53 on this binding element. This was associated with increased SREBP-1c promoter activity and both, mutation in this binding site or p53 over-expression antagonised the effects of CRT knockdown. We, therefore, identify a negatively regulating p53 binding site on the SREBP-1c promoter that is critical during hepatic lipid accumulation. These results were validated in mouse primary hepatocytes and toward a physiological relevance, we report that while the levels of CRT and p53 are reduced in the fatty livers of diabetic db/db mice, SREBP-1c levels are significantly elevated. Our results suggest that decreased CRT levels might be involved in the development of a fatty liver by preventing p53 occupancy on the SREBP-1c promoter and thereby facilitating SREBP-1c up-regulation and consequently, lipid accumulation.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
DAPI, for nucleic acid staining
Sigma-Aldrich
Formaldehyd -Lösung, for molecular biology, 36.5-38% in H2O
Sigma-Aldrich
Oleinsäure, technical grade, 90%
Sigma-Aldrich
1,3-Dimethyl-2-imidazolidinon, ≥99.0% (GC)
Sigma-Aldrich
Palmitinsäure, ≥99%
Sigma-Aldrich
Formaldehyd -Lösung, ACS reagent, 37 wt. % in H2O, contains 10-15% Methanol as stabilizer (to prevent polymerization)
Sigma-Aldrich
Oleinsäure, BioReagent, suitable for cell culture
Sigma-Aldrich
Formaldehyd -Lösung, for molecular biology, BioReagent, ≥36.0% in H2O (T)
Sigma-Aldrich
1,3-Dimethyl-2-imidazolidinon, absolute, over molecular sieve (H2O ≤0.04%), ≥99.5% (GC)
Sigma-Aldrich
Oleinsäure, ≥99% (GC)
Sigma-Aldrich
Palmitinsäure, BioXtra, ≥99%
Sigma-Aldrich
Oleinsäure, meets analytical specification of Ph, Eur., 65.0-88.0% (GC)
Sigma-Aldrich
Oleinsäure, natural, FCC
Sigma-Aldrich
Formaldehyd -Lösung, meets analytical specification of USP, ≥34.5 wt. %
Sigma-Aldrich
1,3-Dimethyl-2-imidazolidinon, reagent grade
Sigma-Aldrich
Palmitinsäure, ≥98%, FCC, FG
Sigma-Aldrich
Palmitinsäure, ≥98% palmitic acid basis (GC)
Sigma-Aldrich
Palmitinsäure, natural, 98%, FG
Sigma-Aldrich
2,2′-Bichinolin-4,4′-dicarbonsäure Dinatriumsalz Dihydrat, ≥98% (HPLC)
Sigma-Aldrich
Formaldehyd-12C -Lösung, 20% in H2O, 99.9 atom % 12C
Sigma-Aldrich
MISSION® esiRNA, targeting human TP53
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Slc6a8
Sigma-Aldrich
MISSION® esiRNA, targeting human CALCR
Sigma-Aldrich
MISSION® esiRNA, targeting human CALR
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Calr